References
- Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon.expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331: 489–95
- Cutlip DE, Chaunhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002; 40: 2082–9
- Jørgensen E, Helqvist J, Clemmensen P, Jensen GVH, Kløvgaard L, Holmvang L,et al Restenosis in bare metal stents: A comparison of follow-up angiograms after 6 months and 4 yerars. Scand Cardiovasc J.
- Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 299 patients. JACC. 1988; 12: 616–23
- Klugherz BD, DeAngelo DL, Kim BK, Herrmann HC, Hirshfeld JW, Kolonsky DM. Three-year clinical follow-up after Palmaz-Schatz stenting. J Am Coll Cardiol. 1996; 27: 1185–91
- Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996; 334: 561–6
- Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitæts Trial (BASKET). Lancet. 2005; 366: 921–9
- Morice MC, Serruys PW, Sousa JE, Fajadet J, Hayashi EB, Perin M, et al. A randomized comparisonof a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–80
- Stone GW, Ellis SG, Cox DA, Hermiller J, O‘Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl Med J. 2004; 350: 221–31
- Kastrati A, Dirschinger J, Boeckstegers P, Elezi S, Schuhlen H, et al. Influence of stent design on 1-year outcome after coronar stent placement: A randomized comparison of five stent types in 1147 unselected patients. Cathet Cardiovasc Intervent. 2000; 50: 290–7
- Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hauleiter J, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003; 41: 1283–8
- Rittersma SZ, de Winter RJ, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Impact of strut thickness on late luminal loss after coronary artery placement. Am J Cardiol. 2004; 93: 477–80
- Simon C, Palmaz JC, Sprague EA. Influence of topography on endothelialisation of stents: Clues for new designs. J Long Term Eff Implants. 2000; 10: 143–51
- Pache J, Dibra A, Mehilli J, Dirschinger J, Schoming A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: A prospective, randomized trial. Eur Heart J. 2005; 26: 1262–8
- Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T. Wallentin L for the SCAAR study group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007; 356: 1009–19
- Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007; 357: 1393–402